Theratechnologies Inc.TSX: TH

Theratechnologies: Financial results for the second quarter and recent operating highlights

· Issued by Theratechnologies Inc. via CNW
-   TH9507 (ThGRF) in Phase III in HIV-associated lipodystrophy
-   Sale of Celmed BioSciences
-   $49 million in liquidities (pro forma)

MONTREAL, July 13 /CNW Telbec/ - Theratechnologies (TSX: TH) announced
today its financial results for the second quarter ended May 31, 2005 and
reviewed recent highlights.
"Through the first half of the year we made solid progress on our
objectives for 2005 and on the longer-term goal of building value for
shareholders," stated Yves Rosconi, President and Chief Executive Officer.
"Our top priority was to initiate the Phase III program and this was
accomplished in June with the first patient beginning treatment in Atlanta,
Georgia. On the financial side, we sold our investment in Celmed BioSciences,
which generated non-dilutive capital and tightened our business focus. We also
completed our management team on schedule bringing two additional
pharmaceutical executives on board. Looking ahead to the next six months, we
will be choosing a second indication for TH9507 and completing the strategic
assessment of our diabetes portfolio," he stated.

Operating highlights:

HIV-associated lipodystrophy

The first patient in the Phase III trial testing TH9507 in HIV-associated
lipodystrophy began treatment in June in Atlanta, Georgia. This disease is
often characterized by an accumulation visceral adipose tissue (VAT),
dyslipidemia and glucose intolerance. Among the 1.1 million HIV-positive
patients in North America and Europe, nearly 200,000 suffer from lipodystrophy
with excess VAT accumulation. The Phase III clinical trial is investigating
the safety and efficacy of TH9507 in reducing excess VAT in approximately
400 patients by administering 2 mg daily for a period of 26 weeks. Results are
expected in the second half of 2006.

Type 2 diabetes program (GLP-1 analogues)

In keeping with its overall strategic approach, Theratechnologies is
currently assessing its market positioning to determine the potential impact
of recent clinical developments involving other GLP-1 analogues. A decision on
the next steps to be taken will be made in the second half of the year.

Sale of investment in Celmed BioSciences

On June 20, the Company completed the sale of its 37% interest in Celmed
Biosciences, a privately held oncology company, for a total consideration of
up to $8.4 million. Total consideration includes an upfront payment of
$2.8 million and milestone payments tied to the success of Celmed's lead
products.

$49 million in liquidities

At May 31, 2005, liquidities (cash, cash equivalents as well as bonds)
amounted to $45.0 million, and tax credits and grants receivable amounted to
$1.2 million, for a total of $46.2 million. Adding the $2.6 million
($2.8 million less related expenses) from the sale of the Celmed shares, the
pro forma liquidities (including the Company's tax credits receivable) would
be $48.8 million. Based on the current burn rate, the Company would be able to
fund its operations for the next three years.

Analyst day

On May 27, the company held an analyst day in Toronto on its Phase III
program in HIV-associated lipodystrophy. The half-day meeting featured
presentations on the disease by Dr. Julian Falutz, lead investigator for the
proposed Canadian study, and Dr. Steven Grinspoon, lead investigator for the
United States. Company management presented clinical and financial details of
the study, as well as the important findings from market research on the
disease. The participants reported back that they were very satisfied with the
information presented.

Four scientific posters at Endo 2005

Researchers from Theratechnologies presented four scientific posters at
the 87th Annual Meeting of the Endocrine Society held in San Diego from
June 4th to June 7th. The posters included data on the lead product, TH9507,
as well as early-stage data related to the diabetes program. The Endocrine
Society's annual meeting is internationally known as the leading source of
state-of-the-art research and clinical advancement in endocrinology and
metabolism.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION:

Consolidation and investments

The consolidated financial statements include the accounts of
Theratechnologies and its subsidiaries. Since July 2nd, 2004, the Company no
longer exercises control over Celmed and the interest in this company is
accounted for by the equity method. Theratechnologies' 2004 consolidated
results include Celmed's results until that date (see note 2 in the notes to
the consolidated financial statements).

Summary of operating results

Consolidated revenues for the three-month period ended May 31, 2005
amounted to $631,000, compared to $782,000 ($555,000 without Celmed) for the
same period in 2004. For the six-month period ended May 31, 2005, consolidated
revenues were $15,733,000, compared to $1,561,000 ($1,074,000 without Celmed)
for the corresponding period in 2004. The increase during the first half of
the year is essentially due to the payment of $14,640,000 (US$12,000,000)
received in connection with the Company's December 2004 agreement with ALZA to
terminate three co-development projects using ALZA's Macroflux(R) transdermal
technology.
Consolidated research and development (R&D) expenditures, before tax
credits and grants, for the second quarter of 2005, totaled $3,246,000,
compared to $5,675,000 ($3,913,000 without Celmed) in 2004. For the six-month
period ended May 31, 2005, R&D expenses reached $6,466,000, compared to
$11,565,000 ($8,012,000 without Celmed). The higher level of expenditures in
2004 is mostly related to activities surrounding ThPTH and TH0318, a GLP-1
analogue (glucagons-like peptide-1). Activities relating to ThPTH ceased
following the agreement with ALZA in December 2004. Development of TH0318 has
been stopped in order to allow the Company to assess its market positioning in
type 2 diabetes.
During the first half of 2005, management reassessed its strategy
regarding non-core products and the related patent portfolio. As a result, the
Company recorded a write off of $444,000 of certain patent costs and deferred
development expenses.
For the second quarter, general and administrative expenses, selling and
market development expenses, patents and amortization of other assets (SG&A)
were $2,425,000 ($1,981,000 before the adjustment to book value of patents and
deferred development expenses referred to above), compared to $2,525,000
($1,685,000 without Celmed) for the same period in 2004. For the six month
period ended May 31, 2005, SG&A expenses were $4,121,000 ($3,677,000 before
the book value adjustment), compared to $4,841,000 ($3,014,000 without Celmed)
for the same period in 2004. The increase in SG&A expenses is mainly due to
preparations required for late-stage development and future commercialization
of TH9507.
For the second quarter of 2005, the proportionate share in loss of Celmed
and Andromed was $5,302,000, compared to $234,000 in 2004. For the six-month
period ended May 31, 2005, the proportionate share in loss of Celmed and
Andromed was $6,449,000, compared to $493,000 in 2004. This increase in the
proportionate share in loss of companies under significant influence is due to
the change to the equity method of accounting of the interest in Celmed, which
only began in the third quarter of fiscal 2004 (see note 2 in the notes to the
consolidated financial statements). In 2004, therefore, the figures represent
only the Company's share of losses in Andromed. This increase is also due to
the non-cash write down, net of related income taxes, of $9,685,000 recorded
by Celmed at May 31, 2005 in connection with the acquisition of NewBiotics'
intellectual property in 2004.
On June 20, 2005, the Company completed the sale of its 37,3% interest in
Celmed BioSciences for total proceeds of up to $8,400,000. The proceeds
include an upfront payment of $2,811,000, as well as milestone payments tied
to the success of Celmed's more advanced products totalling $5,589,000. The
milestone payments will be recorded once the related milestones are reached.
The book value of the investment in Celmed at May 31st reflects the upfront
payment, less the related expenses. Consequently, a non-cash write down of
$2,659,000 was recorded in the second quarter.
The Company recorded an operating loss for the three-month period ended
May 31, 2005 of $4,784,000 (before proportionate share in loss of companies
under significant influence and gains on investments in companies and gains on
dilution, non-controlling interest and discontinued operations), compared to
an operating loss of $6,832,000 for the same period in 2004. The net loss for
the second quarter of 2005 was $12,745,000, compared to a net loss of
$5,910,000 in 2004. For the six-month period ended May 31, 2005, the net loss
was $3,474,000, compared to $7,793,000 in 2004.

Quarterly financial information

The selected financial information provided below is derived from the
Company's unaudited quarterly financial statements for each of the last eight
quarters. This quarterly information has been restated pursuant to the change
in accounting policy related to stock-based remuneration and other payments
described in the 2004 Annual Report, and in order to account for discontinued
operations. This information includes Celmed's results until July 2, 2004.
(See note 2 in the notes to the consolidated financial statements).

<<
-------------------------------------------------------------------------
-------------------------------------------------------------------------
                            2005
-------------------------------------------------------------------------
                              Q2          Q1
-------------------------------------------------------------------------
Revenues               $     631   $  15,102
Operating
 earnings (loss) (1)   $  (4,784)  $  10,418
Earnings (loss)
 from continuing
 operations (2)        $ (12,745)  $   9,271
Net earnings
 (loss)                $ (12,745)  $   9,271
Basic and diluted
 earnings (loss)
 per share:
  Continuing
   activities (2)      $   (0.36)  $    0.26
Net earnings (loss)    $   (0.36)  $    0.26
-------------------------------------------------------------------------
-------------------------------------------------------------------------

-------------------------------------------------------------------------
-------------------------------------------------------------------------
                            2004
-------------------------------------------------------------------------
                              Q4          Q3          Q2          Q1
-------------------------------------------------------------------------
 Revenues              $     503   $     585   $     782   $     779
 Operating
  earnings (loss) (1)  $  (4,655)  $  (4,289)  $  (6,832)  $  (7,094)
 Earnings (loss)
  from continuing
  operations (2)       $ (10,873)  $  (4,137)  $  (6,139)  $  (1,731)
 Net earnings
  (loss)               $ (10,873)  $  (4,150)  $  (5,910)  $  (1,883)
 Basic and diluted
  earnings (loss)
  per share:
   Continuing
    activities (2)     $   (0.31)  $   (0.12)  $   (0.17)  $   (0.06)
 Net earnings (loss)   $   (0.31)  $   (0.12)  $   (0.17)  $   (0.06)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

-------------------------------------------------------------------------
-------------------------------------------------------------------------
                            2003
-------------------------------------------------------------------------
                              Q4          Q3
-------------------------------------------------------------------------
 Revenues              $     897   $     941
 Operating
  earnings (loss) (1)  $  (7,805)  $  (6,694)
 Earnings (loss)
  from continuing
  operations (2)       $  (7,771)  $  (6,232)
 Net earnings
  (loss)               $ (14,079)  $  (6,581)
 Basic and diluted
  earnings (loss)
  per share:
   Continuing
    activities (2)     $   (0.25)  $   (0.20)
 Net earnings (loss)   $   (0.46)  $   (0.21)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

(1) Before restructuring costs, proportionate share in loss of a company
    under significant influence, gains on investments in companies and
    gains on dilution, discontinued operations and non-controlling
    interest
(2) Net of non-controlling interest


Financial position

Theratechnologies maintains a sound cash position. At May 31, 2005,
liquidities (cash and cash equivalents as well as bonds) amounted to
$45,009,000 and tax credits and grants receivable amounted to $1,246,000, for
a total of $46,255,000. Adding the $2,565,000 ($2,811,000 less related
expenses) from the sale of the investment in Celmed the pro forma liquidities
(including the Company's tax credits receivable) would be $48,820,000.
For the three-month period ended May 31, 2005, the burn rate from
operating activities, excluding changes in operating assets and liabilities,
was $3,953,000, compared to a burn rate of $6,138,000 ($4,101,000 without
Celmed) in 2004. For the six-month period ended May 31, 2005, cash from
operating activities, excluding changes in operating assets and liabilities,
was $6,755,000, compared to a burn rate of $12,608,000 ($8,390,000 without
Celmed) in 2004, reflecting the payment from ALZA and lower R&D expenses as
described above.
At July 12, 2005, the number of shares issued and outstanding was
35,549,019, while outstanding options granted under the stock option plan were
2,488,161. In addition, 1,280,000 warrants were outstanding.
During the quarter, there were no material changes in contractual
obligations, other than in the ordinary course of business.
Economic and industry factors were substantially unchanged from those
reported in the Company's 2004 annual report.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company
engaged in the discovery and development of therapeutic peptides in the field
of endocrinology and metabolism. The Company uses proprietary discovery
technologies to expand its product portfolio. The most advanced clinical
program (Phase III) targets HIV-associated lipodystrophy with its lead
compound, TH9507 (ThGRF). The Company is evaluating other potential
indications for TH9507 and it has an interesting product pipeline targeting
type 2 diabetes.

Additional information about Theratechnologies

Further information relating to Theratechnologies is available on the
Company's website at http://www.theratech.com/ . The Company is listed on the
Toronto Stock Exchange under the symbol TH. Additional information, including
the Company's Annual Information Form, is available on SEDAR at
www.sedar.com .

This press release contains forward-looking statements that reflect
Company's current views with respect to its short-term objectives. These
statements involve numerous risks and uncertainties and the Company does not
undertake to update this information. Investors are cautioned against placing
undue importance on forward-looking information contained herein and should
consult the Company's 2004 Annual Report, which contains a analysis of risks
and uncertainties connected to the businesses of the Company.


THERATECHNOLOGIES INC.
CONSOLIDATED BALANCE SHEET
(in thousands of dollars)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
                                                      May 31 November 30
                                                        2005        2004
-------------------------------------------------------------------------
                                                  (unaudited)   (audited)
Assets

Current assets:
  Cash and cash equivalents                     $     7,599  $       436
  Bonds                                              11,677       17,513
  Accounts receivable                                   345          395
  Tax credits receivable                              1,246          754
  Research supplies                                   2,620        1,542
  Prepaid expenses                                      597          202
-------------------------------------------------------------------------
                                                     24,084       20,842

Bonds                                                25,733       24,105

Investments in public companies
  (market value : $2,759 in 2005; $3,026 in 2004)     1,060        1,362

Investment in a private company (note 2)              2,565       11,367

Property and equipment                                2,280        2,234

Other assets (note 3)                                 8,101        8,040
-------------------------------------------------------------------------
                                                $    63,823  $    67,950
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Liabilities and Shareholders' Equity

Current liabilities:
  Accounts payable and accrued liabilities      $     4,120  $     4,996

Shareholders' equity:
  Capital stock (note 4)                            155,654      155,594
  Contributed surplus                                 2,420        2,257
  Deficit                                           (98,371)     (94,897)
-------------------------------------------------------------------------
                                                     59,703       62,954
Subsequent event (note 10)
-------------------------------------------------------------------------
                                                $    63,823  $    67,950
-------------------------------------------------------------------------
-------------------------------------------------------------------------

See accompanying notes to unaudited consolidated financial statements.


THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENT OF EARNINGS
PERIODS ENDED MAY 31
(in thousands of dollars, except per share amounts) (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
                               Second quarter             Six months
                             2005         2004         2005        2004
-------------------------------------------------------------------------


Revenues:
  Royalties,
   technologies and
   other (note 5)     $       158  $        60  $    14,830  $       139
  Interest                    473          722          903        1,422
-------------------------------------------------------------------------
                              631          782       15,733        1,561

Operating costs
 and expenses:
  Research and
   development              3,246        5,675        6,466       11,565
  Tax credits                (256)        (586)        (488)        (919)
-------------------------------------------------------------------------
                            2,990        5,089        5,978       10,646
  General and
   administrative           1,364        2,025        2,687        3,987
  Selling and market
   development                363          293          585          446
 "Patents and amortization
   of other assets
  (note 3)"                   698          207          849          408
-------------------------------------------------------------------------
                            5,415        7,614       10,099       15,487
-------------------------------------------------------------------------

Operating (loss)
 earnings before
 undernoted items          (4,784)      (6,832)       5,634      (13,926)

Proportionate share in loss
 of companies under
 significant influence     (5,302)        (234)      (6,449)        (493)

(Loss) gains on investments
 in companies and gains
 on dilution (note 6)      (2,659)          89       (2,659)       4,743
-------------------------------------------------------------------------
Loss from continuing
 operations before
 non-controlling
 interest                 (12,745)      (6,977)      (3,474)      (9,676)

Gain from discontinued
 operations (note 7)            -          386            -          131

Non-controlling interest        -          681            -        1,752
-------------------------------------------------------------------------
Net loss              $   (12,745) $    (5,910) $    (3,474) $    (7,793)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Basic and diluted loss
 per share (note 4 b):
  Continuing operations
   net of non-
   controlling
   interest           $     (0.36) $     (0.18) $     (0.10) $     (0.24)
  Discontinued operations
   net of non-
   controlling
   interest           $         -  $      0.01  $         -  $      0.01
  Net loss            $     (0.36) $     (0.17) $     (0.10) $     (0.23)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average
 number of common
 shares outstanding    35,524,730   35,466,118   35,519,201   33,470,291
-------------------------------------------------------------------------
-------------------------------------------------------------------------
See accompanying notes to consolidated financial statements.


THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
PERIODS ENDED MAY 31
(in thousands of dollars) (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
                              Second quarter              Six months
                             2005         2004         2005         2004
-------------------------------------------------------------------------
Cash flows from operating
 activities:
  Net loss            $   (12,745) $    (5,910) $    (3,474) $    (7,793)
  Adjustments for:
    Depreciation of
      property and
      equipment               139          271          275          533
    Depreciation of
     other assets             563          137          683          268
    Stock-based
     compensation             129          286          163          517
    Proportionate
     share in loss
     of companies
     under significant
     influence              5,302          234        6,449          493
    Loss (gains) on
     investments in
     companies and
     gains on dilution      2,659          (89)       2,659       (4,743)
    Gain from discontinued
     operations                 -         (386)           -         (131)
    Non-controlling
     interest                   -         (681)           -       (1,752)
-------------------------------------------------------------------------
                           (3,953)      (6,138)       6,755      (12,608)

  Change in operating
   assets and liabilities:
    Interest receivable
     on bonds                 267         (405)          46          (39)
    Accounts receivable        90         (170)          50         (148)
    Tax credits              (260)        (584)        (492)        (913)
    Research supplies          25          155       (1,738)         274
    Prepaid expenses         (311)        (273)        (395)        (546)
    Accounts payable
     and accrued
     liabilities           (1,625)      (1,485)        (710)      (1,762)
-------------------------------------------------------------------------
                           (1,814)      (2,762)      (3,239)      (3,134)
  Cash used in
   discontinued
   operations                   -         (110)           -         (406)
-------------------------------------------------------------------------
                           (5,767)      (9,010)       3,516      (16,148)

Cash flows from
 financing activities:
  Share issue                  60           49           60       15,721
  Share issue costs             -         (145)           -       (1,127)
-------------------------------------------------------------------------
                               60          (96)          60       14,594
Cash flows from
 investing activities:
  Addition to property
   and equipment             (101)        (138)        (380)        (378)
  Disposal of property
   and equipment                -            -            -          122
  Addition to other assets    (67)        (348)        (191)        (387)
  Acquisition of bonds          -      (17,083)      (7,389)     (26,102)
  Disposal of bonds         7,926        8,871       11,551       29,344
  Fees related to the
   disposal of shares
   in a private company        (4)           -           (4)           -
  Disposal of shares in
   public companies             -          112            -        2,481
  Net investments related
   to discontinued
   operations                   -           10            -           10
-------------------------------------------------------------------------
                            7,754       (8,576)       3,587        5,090

-------------------------------------------------------------------------
Net change in cash and
 cash equivalents           2,047      (17,682)       7,163        3,536

Cash and cash
 equivalents, beginning
 of period                  5,552       21,271          436           53
-------------------------------------------------------------------------
Cash and cash
 equivalents, end
 of period            $     7,599  $     3,589  $     7,599  $     3,589
-------------------------------------------------------------------------
-------------------------------------------------------------------------

See accompanying notes to consolidated financial statements.
See note 9 a) for supplemental cash flow information.


THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF DEFICIT
SIX-MONTH PERIOD ENDED MAY 31
(in thousands of dollars)  (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
                                                       2005         2004
-------------------------------------------------------------------------
Deficit, beginning of year                      $   (94,897) $   (70,922)

Net loss                                             (3,474)      (7,793)

Share issue costs                                         -       (1,171)
-------------------------------------------------------------------------
Deficit, end of period                          $   (98,371) $   (79,886)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

See accompanying notes to consolidated financial statements.



THERATECHNOLOGIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
PERIODS ENDED MAY 31, 2005
(in thousands of dollars, except per share amounts) (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

1. Basis of presentation

The financial statements included in this report are unaudited and
reflect normal and recurring adjustments, which are in the opinion of the
Company, considered necessary for a fair presentation. These financial
statements have been prepared in conformity with Canadian generally accepted
accounting principles. The same accounting policies as described in the
Company's latest annual report have been used. However, these financial
statements do not include all disclosures required under generally accepted
accounting principles and accordingly should be read in connection with the
financial statements and the notes thereto included in the Company's latest
annual report. These interim financial statements have not been reviewed by
auditors.

2. Significant accounting policies

Consolidation and investments

The consolidated financial statements include the accounts of the Company
and its subsidiaries. All significant intercompany transactions and balances
have been eliminated.
The investment in public companies is composed of the investment in
Andromed Inc. ("Andromed") and in Ecopia BioSciences Inc. ("Ecopia").
The investment in Andromed Inc. ("Andromed"), a company under significant
influence, has been accounted for by the equity method. The investment in
Ecopia BioSciences Inc., a portfolio investment, is recorded at cost.
On July 2, 2004, Celmed BioSciences Inc. ("Celmed") acquired NewBiotics
Inc. and issued shares from its capital stock to the shareholders of the
acquired company. Consequently, Theratechnologies' interest in Celmed
decreased from 59.7% to 42%. An adjustment clause in connection with the
interest of founding investors could reduce the Company's interest to 37.3%.
Since the date of this transaction, the Company no longer exercises control
over Celmed and the interest in this company is accounted for by the equity
method.
In June 2005, Theratechnologies sold the totality of its shares in Celmed
(see note 10). As of May 31, 2005, the investment in this company is recorded
at the upfront payments to be received amount less related expenses.

3. Other assets

During the first half of 2005, management reassessed its strategy
regarding non-core products and the related patent portfolio. As a result, the
Company recorded a write off of $444 of certain patent costs and deferred
development expenses.

4. Capital stock

-------------------------------------------------------------------------
-------------------------------------------------------------------------
                                                     May 31  November 30
                                                       2005         2004
-------------------------------------------------------------------------

Authorized in unlimited number and
 without par value:
  Common shares
  Preferred shares issuable in one
   or more series
Issued:
  35,549,019 common shares (35,513,549 in 2004)  $  155,654   $  155,594
-------------------------------------------------------------------------
-------------------------------------------------------------------------

During the second quarter of 2005, the Company issued 35,470 shares for
cash consideration of $60.

a)  Stock-based compensation and other stock-based payments

The weighted-average fair value of the 415,000 options granted during the
six-month period ended May 31, 2005 is $0.97 per option. The fair value of the
options granted during 2005 was estimated at the date of grant using the  
Black-Scholes option pricing model with the following assumptions: risk-free
interest rate of 3.77%, expected dividend yield of nil, expected volatility of
51% and an average expected option life of 6 years.

b)  Diluted loss per share

Diluted loss per share were not presented as the effect of options and
warrants would have been anti-dilutive. Furthermore, the exercise of options
and warrants would not have been considered in such computation since their
exercise prices were higher than the average market price during the reporting
periods of 2004 and 2005.

5. Royalties, technologies and other

In December 2004, the Company completed an agreement to terminate three
co-development projects using ALZA Corporation's Macroflux(R) transdermal
technology. The Company retains the rights to develop its molecules with all
other means of delivery and ALZA retains the commercialization rights to
Macroflux(R) with other molecules. In this regard, the Company received a
payment of $14,640 (US $12,000).

6. Loss (gains) on investments in companies and gains on dilution

During the quarters ended February 29, 2004 and May 31, 2004, the Company
realized gains on investments in companies of $1,929 and $89 respectively,
resulting from the sale of shares in public companies.
In January and February 2004, Celmed's institutional investors exercised
adjustment clauses in relation to their investment, thus reducing the
Company's interest in Celmed from 61.6% to 56.1%. In February 2004, Celmed
proceeded with the redemption for a nominal amount of shares of certain
shareholders because the milestones related to these shares were not achieved.
In April 2004, Celmed proceeded with the redemption of shares of a          
non-controlling shareholder in connection with the sale of a US subsidiary.
These redemptions resulted in an increase of the Company's interest in Celmed
to 59.7%.
Consequently, the deferred gain of $3,762 at November 30, 2003 was
attributed to non-controlling interests, and the adjustment to their interest
resulted in a gain of $2,725, which is included in the statement of earnings
for the period ended February 29, 2004.
On May 31, 2005, the Company recorded a reduction in value of $2,659 in
relation to the sale of its shares in Celmed on June 20, 2005 (see note 10).

7. Discontinued operations

During the first quarter of 2004, Celmed studied the relevance of
pursuing its activities in the treatment of Parkinson's disease. In this
context, Celmed discontinued its development activities for this program. In
April 2004, Celmed disposed of the shares of its US subsidiary in the field of
neurology.
Consequently, operating results for these activities have been
reclassified under item "Discontinued operations". The results are shown
below:

-------------------------------------------------------------------------
-------------------------------------------------------------------------
                               Second quarter             Six months
                             2005         2004         2005         2004
-------------------------------------------------------------------------

Costs and expenses:
  General and
   administrative    $          -  $       (58) $         -  $       (42)
  Research and
   development                  -          104            -          322
  Patents and
   amortization of
   other assets                 -            -            -           21
  Gain on disposal
   of subsidiary                -         (432)           -         (432)
-------------------------------------------------------------------------
Gain from
 discontinued
 operations          $          -  $       386  $         -  $       131
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Gain from
 discontinued
 operations
 attributable to
 parent company      $          -  $       229  $         -  $        77
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Non-controlling
 interest before
 discontinued
 activities          $          -  $       838  $         -  $     1,806
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Loss from
 continuing
 operations, net
 of non-controlling
 interest            $    (12,745) $    (6,139) $    (3,474) $    (7,870)
-------------------------------------------------------------------------
-------------------------------------------------------------------------


8.    Segmented information

-------------------------------------------------------------------------
                                                    Intersegment
                                                    adjustments
                  Therapeutic    Cell       Other       and
                    peptides   therapy    segments  eliminations  Total
-------------------------------------------------------------------------

Second quarter
 ended May 31, 2005

Revenues from
 external
 customers          $    150   $      -   $      -   $      -   $    150
Revenues from
 companies under
 significant
 influence                 8          -          -          -          8
Loss from
 continuing
 operations           (4,784)    (5,149)      (153)    (2,659)   (12,745)
Net loss              (4,784)    (5,149)      (153)    (2,659)   (12,745)
Total assets          60,527      2,565      1,060       (329)    63,823

Six months ended
 May 31, 2005

Revenues from
 external
 customers          $ 14,810   $      -   $      -   $      -   $ 14,810
Revenues from
 companies under
 significant
 influence                20          -          -          -         20
Earnings (loss)
 from continuing
 operations            5,634     (6,147)      (302)    (2,659)    (3,474)
Net earnings
 (net loss)            5,634     (6,147)      (302)    (2,659)    (3,474)
Total assets          60,527      2,565      1,060       (329)    63,823
-------------------------------------------------------------------------
-------------------------------------------------------------------------

-------------------------------------------------------------------------
                                                    Intersegment
                                 Cell               adjustments
                  Therapeutic  therapy      Other       and
                    peptides     (1)      segments  eliminations  Total
-------------------------------------------------------------------------

Second quarter
 ended May 31, 2004

Revenues from
 external
 customers          $     60   $      -   $      -   $      -   $     60
Intersegment
 revenues                 21          -          -        (21)         -
Loss from
 continuing
 operations           (4,587)    (1,892)      (234)       574     (6,139)
Net loss              (4,587)    (1,663)      (234)       574     (5,910)
Total assets          62,251     31,579      1,439       (112)    95,157

Six months ended
 May 31, 2004

Revenues from
 external
 customers          $    139   $      -   $      -   $      -   $    139
Intersegment
 revenues                 42          -          -        (42)         -
Loss from
 continuing
 operations           (9,284)    (4,392)      (493)     6,299     (7,870)
Net Loss              (9,284)    (4,315)      (493)     6,299     (7,793)
Total assets          62,251     31,579      1,439       (112)    95,157
-------------------------------------------------------------------------
-------------------------------------------------------------------------

(1) The 2004 net loss for this sector was reduced by the non-controlling
    interest.

9. Supplemental information

a)  The following transactions were concluded by the Company and did not
    impact cash flow.

-------------------------------------------------------------------------
-------------------------------------------------------------------------
                                                      May 31      May 31
                                                        2005        2004
-------------------------------------------------------------------------

Addition to property and equipment financed
 by accounts payable and accrued liabilities      $      190  $       24

Addition to other assets financed by
 accounts payable and accrued liabilities                 22         388

Share issue cost financed by accounts
 payable and accrued liabilities                           -          44
-------------------------------------------------------------------------

b)  General and administrative expenses include a gain on exchange of
    $47 for the second quarter of 2005 (loss of $5 in 2004) and a loss of
    $3 for the six-month period ended May 31, 2005 (gain of $40 in 2004).

10. Subsequent event

On June 20, 2005, the Company completed the sale of its 37,3% interest in
Celmed BioSciences for total proceeds of up to $8,400. The acquirer is a group
of minority shareholders of Celmed.
The proceeds include an upfront payment of $2,811, as well as milestone
payments tied to the success of Celmed's more advanced products totalling
$5,589. The milestone payments will be recorded once the related milestones
are reached.
>>

Theratechnologies Inc. on 6ix

Story so far

Earlier from Theratechnologies

Later from Theratechnologies

All Theratechnologies news releases